Cerebral Venous Sinus Thrombosis
Conditions
Interventions
experimental group:Venous Thrombectomy Stent
Sponsors
Xuanwu Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18-70 years; 2. Cerebral venous sinus thrombosis (from onset to diagnosis less than 28 days) confirmed by cerebral angiography, magnetic resonance venography or computed tomographic venography; 3. Severe form of CVT with a high chance of incomplete recovery, as defined by the presence of one or more of the following risk factors; (1) Clinical deterioration or progression despite anticoagulation; (2) Stupor, Coma or mental status disorder; (3) Involvement of multiple sinus veins results in severe high cranial pressure or rapid vision loss; (4) Venous infarction or intracranial hemorrhage with high load venous sinus thrombosis; (5) Thrombosis of the deep cerebral venous system and straight sinus; 4. Life expectancy > 1 year; 5. The subject (or his/her guardian) agrees to participate in this study and signs the informed consent.
Exclusion criteria
Exclusion criteria: 1. Isolated cavernous sinus thrombosis or isolated cortical vein thrombosis; 2. mRS > 2 before CVST; 3. Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions , which requires emergency decompression; 4. Recurrent CVST; 5. Pregnancy (Excluding women more than 6 weeks postpartum); 6. Recent (< 2 weeks) major surgical procedure or severe cranial trauma; 7. Any known serious condition (such as terminal cancer) with a poor short term (<1 year) prognosis; 8. Contraindication for anti-coagulant or thrombolytic treatment; (1) Documented generalized bleeding disorder; (2) Thrombocytopenia (<100 x 10^9/L); (3) Severe hepatic or renal dysfunction, that interferes with normal coagulation; (4) Gastrointestinal tract hemorrhage (< 3 months, not including hemorrhage from rectal hemorrhoids); 9. Known allergy to nickel and titanium; 10. Known allergy against contrast used during endovascular procedures or the thrombolytic or anticoagulation drug used; 11. Patients who had participated in other clinical trials within three months; 12. Other conditions judged by the researcher to be unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immediately postoperative recanalization rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| The time of thrombectomy procedure;The ratio of functional independence (modified Rankin score 0-2);Glasgow coma scale (GCS);The proportion of symptom-free and improved;Lumbar puncture cerebrospinal fluid pressure;The recurrence rate of cerebral venous sinus thrombosis; | — |
Countries
China
Contacts
Public ContactJi Xunming
Xuanwu Hospital Affiliated to Capital Medical University
Outcome results
None listed